Cargando…

Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006

BACKGROUND: Escherichia coli is the commonest cause of community and nosocomial urinary tract infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used antimicro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bean, David C, Krahe, Daniel, Wareham, David W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440378/
https://www.ncbi.nlm.nih.gov/pubmed/18564430
http://dx.doi.org/10.1186/1476-0711-7-13
_version_ 1782156540660154368
author Bean, David C
Krahe, Daniel
Wareham, David W
author_facet Bean, David C
Krahe, Daniel
Wareham, David W
author_sort Bean, David C
collection PubMed
description BACKGROUND: Escherichia coli is the commonest cause of community and nosocomial urinary tract infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used antimicrobial agents amongst all urinary isolates obtained over a 12 month period. METHODS: Antimicrobial susceptibility to ampicillin, amoxicillin/clavulanate, cefalexin, ciprofloxacin, gentamicin, nitrofurantoin, trimethoprim and cefpodoxime was determined for 11,865 E. coli urinary isolates obtained from community and hospitalised patients in East London. RESULTS: Nitrofurantoin was the most active agent (94% susceptible), followed by gentamicin and cefpodoxime. High rates of resistance to ampicillin (55%) and trimethoprim (40%), often in combination were observed in both sets of isolates. Although isolates exhibiting resistance to multiple drug classes were rare, resistance to cefpodoxime, indicative of Extended spectrum β-lactamase production, was observed in 5.7% of community and 21.6% of nosocomial isolates. CONCLUSION: With the exception of nitrofurantoin, resistance to agents commonly used as empirical oral treatments for UTI was extremely high. Levels of resistance to trimethoprim and ampicillin render them unsuitable for empirical use. Continued surveillance and investigation of other oral agents for treatment of UTI in the community is required.
format Text
id pubmed-2440378
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24403782008-06-27 Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006 Bean, David C Krahe, Daniel Wareham, David W Ann Clin Microbiol Antimicrob Research BACKGROUND: Escherichia coli is the commonest cause of community and nosocomial urinary tract infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used antimicrobial agents amongst all urinary isolates obtained over a 12 month period. METHODS: Antimicrobial susceptibility to ampicillin, amoxicillin/clavulanate, cefalexin, ciprofloxacin, gentamicin, nitrofurantoin, trimethoprim and cefpodoxime was determined for 11,865 E. coli urinary isolates obtained from community and hospitalised patients in East London. RESULTS: Nitrofurantoin was the most active agent (94% susceptible), followed by gentamicin and cefpodoxime. High rates of resistance to ampicillin (55%) and trimethoprim (40%), often in combination were observed in both sets of isolates. Although isolates exhibiting resistance to multiple drug classes were rare, resistance to cefpodoxime, indicative of Extended spectrum β-lactamase production, was observed in 5.7% of community and 21.6% of nosocomial isolates. CONCLUSION: With the exception of nitrofurantoin, resistance to agents commonly used as empirical oral treatments for UTI was extremely high. Levels of resistance to trimethoprim and ampicillin render them unsuitable for empirical use. Continued surveillance and investigation of other oral agents for treatment of UTI in the community is required. BioMed Central 2008-06-18 /pmc/articles/PMC2440378/ /pubmed/18564430 http://dx.doi.org/10.1186/1476-0711-7-13 Text en Copyright © 2008 Bean et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bean, David C
Krahe, Daniel
Wareham, David W
Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title_full Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title_fullStr Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title_full_unstemmed Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title_short Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006
title_sort antimicrobial resistance in community and nosocomial escherichia coli urinary tract isolates, london 2005 – 2006
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440378/
https://www.ncbi.nlm.nih.gov/pubmed/18564430
http://dx.doi.org/10.1186/1476-0711-7-13
work_keys_str_mv AT beandavidc antimicrobialresistanceincommunityandnosocomialescherichiacoliurinarytractisolateslondon20052006
AT krahedaniel antimicrobialresistanceincommunityandnosocomialescherichiacoliurinarytractisolateslondon20052006
AT warehamdavidw antimicrobialresistanceincommunityandnosocomialescherichiacoliurinarytractisolateslondon20052006